Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831283 · ClinicalTrials.gov registry record · Phase 2
Imaging Inflammation in Alzheimer's Disease
A Phase 2 study, sponsored by Patrick Lao.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02831283 is a Phase 2 study that has completed, run by Patrick Lao. The registered enrollment target is 60 participants.
The verdict
NCT02831283, a Phase 2 study, has completed, sponsored by Patrick Lao.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
Interventions
- DRUG 18F-Florbetaben
- DRUG 11C-PBR28
- PROCEDURE Lumbar puncture (optional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-06 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02831283
The ClinicalTrials.gov registry entry for NCT02831283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Lao, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 18F-Florbetaben is the first listed.
NCT02831283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02831283 about?
NCT02831283 is a clinical study titled "Imaging Inflammation in Alzheimer's Disease". This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to ...
What is the current status of trial NCT02831283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-06. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02831283?
The interventions under investigation include: 18F-Florbetaben (DRUG), 11C-PBR28 (DRUG), Lumbar puncture (optional) (PROCEDURE).
Who is sponsoring clinical trial NCT02831283?
This trial is sponsored by Patrick Lao, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.